How Kelderman was paid
$8.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Kim KeldermanPresident and CEO | $936,000 | $3,929,942 | $1,932,848 | $1,318,917 | $33,473 | $8,151,181 |
| James HippelExecutive Vice President and CFO | $723,000 | $4,453,020 | $907,273 | $926,163 | $17,926 | $7,027,382 |
| William GeistPresident, Protein Sciences | $573,200 | $1,206,585 | $593,448 | $748,026 | $18,040 | $3,139,299 |
| Matthew McManusPresident, Diagnostics and Spatial Biology | $572,000 | $1,213,200 | $596,695 | $444,787 | $19,937 | $2,846,619 |
| Shane BohnenSenior Vice President and General Counsel | $431,000 | $767,575 | $377,496 | $386,478 | $18,183 | $1,980,732 |
What changed and why
- $8.2M$8,151,181 CEO total compensation increased from $6,852,495 in fiscal 2024.
- 50%50% of equity awards are performance-vesting RSUs, with 25% time-vesting RSUs and 25% stock options.
- Relative TSR was introduced as a performance metric, with a negative cap on relative TSR payouts.
- 105%105% is the maximum organic-revenue bonus payout band, while adjusted EBITA’s maximum is 108%.
- 35%35% of shareholders supported say-on-pay in 2023, prompting a comprehensive compensation-program review.
- Enterprise performance goals will be modeled during fiscal 2026 for possible formal adoption in fiscal 2027.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.